Harel Insurance Investments & Financial Services Ltd. decreased its stake in CVS Health Co. (NYSE:CVS) by 6.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,648 shares of the pharmacy operator’s stock after selling 304 shares during the period. Harel Insurance Investments & Financial Services Ltd.’s holdings in CVS Health were worth $1,116,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Cable Hill Partners LLC grew its holdings in CVS Health by 2.8% in the fourth quarter. Cable Hill Partners LLC now owns 4,964 shares of the pharmacy operator’s stock worth $339,000 after purchasing an additional 135 shares during the period. San Francisco Sentry Investment Group CA lifted its stake in shares of CVS Health by 2.4% during the 1st quarter. San Francisco Sentry Investment Group CA now owns 5,695 shares of the pharmacy operator’s stock valued at $428,000 after buying an additional 135 shares in the last quarter. Gofen & Glossberg LLC IL raised its stake in shares of CVS Health by 0.5% during the 1st quarter. Gofen & Glossberg LLC IL now owns 29,941 shares of the pharmacy operator’s stock valued at $2,252,000 after purchasing an additional 137 shares during the period. Ausdal Financial Partners Inc. lifted its holdings in CVS Health by 2.4% during the 4th quarter. Ausdal Financial Partners Inc. now owns 6,200 shares of the pharmacy operator’s stock worth $423,000 after purchasing an additional 143 shares in the last quarter. Finally, RiverGlades Family Offices LLC grew its holdings in CVS Health by 2.3% during the 4th quarter. RiverGlades Family Offices LLC now owns 6,650 shares of the pharmacy operator’s stock valued at $454,000 after buying an additional 150 shares in the last quarter. 74.21% of the stock is currently owned by institutional investors and hedge funds.
CVS has been the subject of several recent analyst reports. Truist Securities boosted their price objective on shares of CVS Health from $80.00 to $88.00 and gave the company a “buy” rating in a research note on Tuesday, April 20th. Guggenheim reaffirmed a “neutral” rating on shares of CVS Health in a report on Tuesday, March 23rd. Jefferies Financial Group upgraded shares of CVS Health from a “hold” rating to a “buy” rating and set a $90.00 price objective on the stock in a research report on Friday, January 8th. Truist raised their price objective on CVS Health from $80.00 to $88.00 in a report on Wednesday, April 14th. Finally, Morgan Stanley upped their target price on CVS Health from $86.00 to $92.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 20th. Four analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. CVS Health presently has a consensus rating of “Buy” and a consensus price target of $84.31.
In other CVS Health news, SVP James David Clark sold 5,350 shares of the firm’s stock in a transaction that occurred on Wednesday, March 31st. The shares were sold at an average price of $76.00, for a total transaction of $406,600.00. Also, EVP Thomas M. Moriarty sold 103,423 shares of CVS Health stock in a transaction that occurred on Wednesday, April 21st. The shares were sold at an average price of $77.00, for a total transaction of $7,963,571.00. Following the transaction, the executive vice president now owns 103,423 shares of the company’s stock, valued at $7,963,571. The disclosure for this sale can be found here. In the last 90 days, insiders sold 583,892 shares of company stock valued at $43,918,083. 0.46% of the stock is currently owned by company insiders.
NYSE:CVS opened at $77.69 on Tuesday. The company has a quick ratio of 0.67, a current ratio of 0.95 and a debt-to-equity ratio of 0.89. The firm’s fifty day simple moving average is $74.98 and its 200 day simple moving average is $70.72. The stock has a market cap of $101.88 billion, a P/E ratio of 12.84, a price-to-earnings-growth ratio of 1.72 and a beta of 0.82. CVS Health Co. has a twelve month low of $55.36 and a twelve month high of $78.22.
CVS Health (NYSE:CVS) last announced its earnings results on Monday, February 15th. The pharmacy operator reported $1.30 earnings per share for the quarter, beating analysts’ consensus estimates of $1.24 by $0.06. CVS Health had a net margin of 2.99% and a return on equity of 15.60%. The firm had revenue of $69.55 billion for the quarter, compared to analyst estimates of $68.67 billion. During the same quarter in the previous year, the firm posted $1.73 EPS. On average, analysts expect that CVS Health Co. will post 7.43 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Monday, May 3rd. Stockholders of record on Friday, April 23rd were given a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 2.57%. The ex-dividend date was Thursday, April 22nd. CVS Health’s dividend payout ratio is currently 28.25%.
CVS Health Company Profile
CVS Health Corporation provides health services in the United States. The company's Pharmacy Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, clinical, and disease and medical spend management services.
Read More: Penny Stocks, Risk and Reward Factors
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Co. (NYSE:CVS).
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.